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Abstract  
Gambiense human African trypanosomiasis (g-HAT) is a parasitic infection that usually progresses to 
coma and death unless treated. The WHO has updated its guidelines for the treatment of g-HAT based 
on independent literature reviews and using the GRADE methodology. The first-line treatment 
options, pentamidine and nifurtimox-eflornithine combination therapy (NECT), have been expanded 
to include fexinidazole, an oral monotherapy recently given a positive opinion from the European 
Medicines Agency. Fexinidazole is recommended for individuals ≥6 years and ≥20 kg, in first and 
second stage g-HAT with cerebrospinal fluid leukocytosis <100/µl. NECT remains recommended for 
those with ≥100 leukocytes/µl. Without clinical suspicion of severe second stage, lumbar puncture 
can be avoided and fexinidazole given. Fexinidazole should only be administered under supervision 
of trained health staff. As these recommendations are expected to change clinical practice 
considerably, health professionals should consult the detailed WHO guidelines. These guidelines will 
be updated as evidence accrues. 
 
Introduction 
Human African trypanosomiasis (HAT), or sleeping sickness, is a neglected tropical disease that 
afflicts populations in rural sub-Saharan Africa, where the tsetse fly vector transmits the parasite. Two 
forms of the disease exist: the usually slowly progressing form, known as gambiense HAT (g-HAT), 
caused by Trypanosoma brucei gambiense, endemic in West and Central Africa; and the usually faster 
progressing form, known as rhodesiense HAT, caused by Trypanosoma brucei rhodesiense, endemic 
in eastern and southern Africa.  
 
After devastating epidemics during the 20th century, sustained and coordinated control efforts over 
the past 20 years led to a historically low number of 1 446 reported cases in 2017, the vast majority of 
which were g-HAT (98%). Rhodesiense HAT is mainly a zoonosis that occasionally affects humans. 
The target of eliminating HAT as a public health problem by 2020 with <2 000 HAT cases/year and 
90% reduction of the areas at risk (reporting ≥1 case/10 000 people per year), has therefore nearly 
been met.1,2 This remarkable progress has relied on case-finding and treatment, a strategy that reduces 
transmission by depleting the parasite reservoir in humans, and has been occasionally complemented 
with vector control activities. 
 
The treatment of g-HAT is stage dependent, until now requiring all patients to undergo a systematic 
lumbar puncture and cerebrospinal fluid (CSF) examination, to discriminate between first (hemo-
lymphatic) and second (meningo-encephalitic) stages.3 The recommended first line treatment of first 
stage g-HAT (≤5 white blood cells (WBC)/µL and no trypanosomes in CSF) has been pentamidine. 
Pentamidine is given intramuscularly once daily for 7 days, and can be administered at the primary 
health care level. The first line treatment of second stage g-HAT (>5 WBC/µL and/or trypanosomes 
in CSF) has been nifurtimox (orally in three daily doses for 10 days) and eflornithine (intravenously 
in two daily infusions for 7 days) combination therapy (NECT).3 NECT has been a major 
improvement in therapy, when compared with its predecessors, melarsoprol or eflornithine 
monotherapy.4 However, NECT requires patient hospitalization, intensive nursing and complex drug 
transport logistics.5  
 
Fexinidazole is an effective oral monotherapy against g-HAT.6 In November 2018, the European 
Medicines Agency (EMA) issued a positive opinion for fexinidazole treatment of g-HAT. That 
opinion was framed by article 58, a mechanism designed for drugs intended for use outside the EU.7,8  
In December 2018, marketing authorization was given in the Democratic Republic of Congo which 
harbours most cases of g-HAT.  
 
Fexinidazole is administrated orally once daily for ten days (four days loading dose, six days 
maintenance dose). There is evidence supporting its effectiveness in both disease stages.6 These 
features open the way for clinically significant modifications in the management of g-HAT, such as 
circumventing systematic lumbar puncture and removing the need for injectable treatment in specific 
groups of patients. However, this new drug also has limitations. First, patients with severe central 
nervous system involvement are at higher risk of failing treatment.7 Second, the tablets should be 
taken with a meal because bioavailability is seriously compromised in the unfed state.9  
 
The EMA stated that fexinidazole should be used in line with official recommendations.7 In 
December 2018, the WHO Guideline Development Group on the treatment of HAT met in Geneva to 
provide updated evidence-based recommendations on therapeutic choices for policy makers and 
medical staff. The detailed treatment guidelines on g-HAT, which resulted from this meeting, are 
accessible on the WHO website.10 The objective of this paper is to document the decision process, to 
provide complementary information, to summarize the updated WHO recommendations, and to 
discuss their implications for clinical practice. 
  
Methods 
The WHO developed these guidelines following the methodology outlined in the WHO handbook for 
guideline development.11 The WHO secretariat formed a guidelines development group that included 
individuals with recognized expertise in the field of treatment of HAT, public health, and national 
control programs. The group was co-chaired by a content expert and a guideline methodologist. 
 
In an initial prioritization process, key questions were formulated pertaining to g-HAT treatment and 
outcomes judged important to patients within the context of the disease and its setting. The questions, 
structured in PICO format (population, intervention, comparison, outcomes), were:12 1) Should 
fexinidazole or pentamidine be used for first stage g-HAT; 2) Should fexinidazole or NECT be used 
for second stage g-HAT; 3) Should clinical stratification or lumbar puncture stratification or no 
stratification be used for the treatment of g-HAT; 4) Should inpatient administration or outpatient 
administration under supervision be used for the treatment with fexinidazole.  
 
A systematic review was externally commissioned to synthesize the evidence relevant to the PICO 
questions.13 The full version of the guidelines provides the details of the review, including the search 
strategy, study selection, data extraction, and data analysis.14 The Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) methodology was followed to rate the certainty 
of the evidence for each outcome as high, moderate, low, or very low.15,16 The evidence was then 
summarized by outcome using the `Summary of finding´ tables.15 The tables provide outcome-
specific information concerning the certainty of evidence and the relevant statistical information.15,17  
 
Following the GRADE methodology, the guideline development group shaped the recommendations 
and graded their strength as either strong or conditional.18 The grading considered the following 
factors: the desirable and undesirable effects of the intervention relative to its comparator; the overall 
certainty of the evidence; the values attached to the main outcomes; the balance between desirable and 
undesirable effects; the resource requirements; the impact on health equity; the acceptability of the 
intervention to key stakeholders; and the feasibility.  
 
Results 
Table 1 provides a summary of recommendations addressing the four PICO questions, their strength, 
the certainty of the supporting evidence, and key considerations. Detailed judgements on various 
factors considered when grading the recommendations are provided in the Evidence to Decision tables 
accessible on the WHO website.10 
 
PICO 1: Fexinidazole or pentamidine for the treatment of first stage g-HAT 
The panel suggests using fexinidazole over pentamidine in patients with first stage g-HAT 
(conditional recommendation, very low certainty of evidence).  
So far, no clinical trial compared fexinidazole with pentamidine. Data about fexinidazole treatment of 
first stage patients originate from two prospective, open-label, single-arm studies in adults (n=189) 
(DNDiFEX005) and children (≥6 years old and ≥20 kg, n=69) (DNDiFEX006). Their respective 
findings at 18 months were as follows:14 failure rates of 2·1% and 1·4%, mortality rates of 1·6% and 
1·4%, adverse event rates of 93·1% and 88·4%, and serious adverse event rates of 9·0% and 7·2%.  
For pentamidine treatment of first stage g-HAT, evidence originated from the comparator arm of two 
randomized clinical trials19,20 and nine observational studies21-29 that in total included 6 722 treated 
children and adults. The comparability of these studies is limited due to the heterogeneity of study 
populations, outcome criteria and observation periods. The range of treatment failure rates was 3·9%–
4·6%. Adverse events occurred in 17·6%–98·5% of treated patients and serious adverse events in 
2·4%–17·5%.14  
The balance of desirable and undesirable effects appears to favour fexinidazole. Adverse event rates 
seem to be similar, but the events are of different types. Fexinidazole causes gastro-intestinal events, 
mainly vomiting and nausea, as well as headache, insomnia, tremor, and dizziness. The main adverse 
events for pentamidine are hypotension, nausea, vomiting and pain at the injection site. Information 
was insufficient to compare the direct costs. However, the indirect costs in terms of human resources 
are probably lower for oral fexinidazole treatment, than for intramuscular injection with pentamidine. 
Children aged <6 years and/or <20 kg should receive pentamidine, as the safety and efficacy of 
fexinidazole in this age group has not been established in clinical trials. 
 
PICO 2: Fexinidazole or NECT for the treatment of second stage g-HAT 
The panel suggests using fexinidazole over NECT in patients with second stage g-HAT and CSF WBC 
<100/µl (conditional recommendation, low certainty of evidence). 
The panel suggests using NECT over fexinidazole in patients with second stage g-HAT and CSF WBC 
≥100/µl (conditional recommendation, low certainty of evidence). 
In one randomized, non-inferiority trial, 264 patients ≥15 years with second stage g-HAT, having >20 
WBC/µl or trypanosomes in CSF, were treated with fexinidazole, 130 with NECT.6 Treatment failure 
rates at 24 months were 10·3% with fexinidazole versus 2·4% with NECT (RR 4·36, 95% CI 1·35–
14·11).14 Adverse events at 18 months occurred in 94·0% of patients in the fexinidazole group versus 
93·1% for NECT (RR 1·01, 95% CI 0·95–1·06), serious adverse events in 11·7% versus 10%, 
respectively (RR 1·17, 95% CI  0·64–2·17).14  The most frequently reported adverse events were, 
similar as above: gastro-intestinal (60%), headache, insomnia, asthenia, tremor and dizziness, which 
occurred in a higher percentage for fexinidazole, with the exception of vomiting. The EMA report 
highlighted that in this trial, in patients with second stage g-HAT and CSF ≥100 WBC/µl the failure 
rate at 18 months was significantly higher for fexinidazole (13·1%) than for NECT (1·3%). In 
contrast, in the group with CSF <100 WBC/µl treatment failure rates with fexinidazole and NECT 
were similar, 2·0% and 4·1% respectively.7 Furthermore, data about fexinidazole treatment of second 
stage patients ≥15 years with CSF ≤20 WBC/µl originated from a single-arm study 
(n=41)(DNDiFEX005), with 2·4% treatment failure at 18 months.14 The single arm study in children 
6–15 years with second stage g-HAT (n=56)(DNDiFEX006) revealed 1·8% treatment failure.14 In 
both studies, similar adverse events – gastro-intestinal and CNS related – were observed, as in the 
randomized controlled trial. 
Based on the EMA results, the panel decided to consider the patient group with “severe” second stage 
g-HAT having ≥100 WBC/µl separately and to split the PICO 2 question based on this cut-off.  The 
balance of desirable and undesirable effects did not favour either fexinidazole or NECT if CSF WBC 
<100/µl and favoured NECT if CSF WBC ≥100/µl. Fexinidazole outpatient treatment was judged 
more feasible, requiring relatively little resource and allowing financial savings, probably five- to ten-
fold. NECT requires hospitalization and complex logistics, to deliver the comparatively large volume 
of drugs and accessory materials required for use. Oral treatment allows patients to be treated closer to 
their home, including in remote or unstable settings, which accrues fewer expenses, thus increasing 
health equity. Oral treatment with fexinidazole in non-severe HAT is expected to be the preferred 
treatment option (from the feasibility standpoint) for both the patients and the health system, although 
some patients may perceive intravenous treatment as a better option in serious illness in general.30 
Children aged <6 years and/or with <20 kg should receive NECT, as fexinidazole is not approved for 
this group. 
 
PICO 3: Clinical stratification or lumbar puncture stratification or no stratification for the 
treatment of g-HAT  
The panel suggests doing a lumbar puncture with CSF examination over not doing a lumbar puncture 
(conditional recommendation, very low certainty of evidence). Without clinical suspicion of severe 
second stage, a lumbar puncture can be avoided and fexinidazole preferentially given. 
Until now, selecting treatment for g-HAT has required a systematic lumbar puncture and CSF 
examination for staging. Fexinidazole is effective in both disease stages. However, as stated above, in 
severe second stage (CSF ≥100 WBC/µl) the risk of treatment failure is significantly higher with 
fexinidazole than with NECT.7,14  The panel therefore had to consider the potential benefit of avoiding 
systematic lumbar puncture versus the risk of treatment failure in severe second stage patients.   
The panel suggested that in case of any clinical sign and symptom that raises suspicion of severe 
second stage, lumbar puncture and CSF examination should be performed. In the absence of a 
validated clinical tool for stratification, an ad-hoc group of clinicians and neurologists identified 
symptoms and signs that could be used for selection of patients likely to be in severe second stage. 
The following symptoms and signs, correlating with severe meningo-encephalitic g-HAT and 
assessable in peripheral health facilities, were identified:31,32 mental confusion, abnormal behaviour, 
logorrhoea, speech impairment, anxiety, tremor, motor weakness, ataxia, abnormal gait, abnormal 
movements, and seizures (table 2). The presence of any of these symptoms or signs should raise 
suspicion of severe second stage g-HAT. Although sleep disorder is very common in severe HAT, it 
is also frequent in non-severe HAT, thus this feature alone was not considered sufficient to be 
indicative. Without clinical suspicion of severe second stage, lumbar puncture can be avoided and 
fexinidazole preferentially given, on condition of having high confidence in appropriate follow-up to 
detect relapse early. Avoiding systematic lumbar puncture in a subgroup of patients for treatment 
stratification was judged to allow for moderate savings of human and material resources. As 
fexinidazole is not approved for children <6 years old or <20 kg body weight, they require systematic 
lumbar puncture for disease staging. 
 
PICO 4: Inpatient or outpatient administration of fexinidazole under supervision 
The panel suggests either inpatient or outpatient administration of fexinidazole under supervision 
(conditional recommendation, very low certainty of evidence). 
In the above-mentioned clinical trials, fexinidazole was administered as inpatient treatment. Taken 
without food, the fexinidazole bioavailability is 2·5–3 fold lower and the active metabolites do not 
reach therapeutic levels.9 Incomplete adherence to unsupervised oral treatments is commonly 
reported. The efficacy of fexinidazole as outpatient treatment risks being impaired through non-
adherence and/or sub-therapeutic drug levels if taken without a meal. Therefore, an independent, non-
systematic search was conducted on adherence to oral malaria treatment (predominantly 3-day 
course), as a proxy of the expected adherence to the 10-day fexinidazole oral regimen. Four 
systematic reviews encompassing 133 studies reported high variability of adherence to malaria 
treatment, ranging from 1·5% to 100%. Only one review (25 studies) calculated a pooled prevalence, 
yielding a 69·8% adherence.33-36 Experiencing vomiting, other adverse events, non-supervised first 
dose, lower education or income level, being male, and belief in traditional medicine, were among the 
factors associated with non-adherence to oral malaria treatment.   
Adults treated with fexinidazole reported a higher percentage of psychiatric adverse reactions (39%), 
most mild to moderate, than those treated with NECT (18%).6 One of the most frequent adverse 
reactions reported in adults treated with fexinidazole was vomiting (28–42%), mostly mild to 
moderate without permanent treatment discontinuation under clinical trial conditions in hospitalised 
patients.6,14 Vomiting was more frequent in children (69%).14 These adverse drug reactions were 
recognized as additional threats to the compliance with the 10-day fexinidazole course.  
Administration of fexinidazole should, therefore, be done under the strict supervision of trained health 
staff, who must confirm that the patient is in a fed condition and who must directly observe each drug 
intake. The panel suggested administering fexinidazole in outpatient mode only if there is confidence 
in concomitant food intake, confidence in full adherence, absence of psychiatric disorders (history or 
acute), and if bodyweight is ≥35 kg (below 35 kg the dose is smaller and drug exposure margins are 
narrower). This can be done in hospitals or peripheral health facilities, and, in particular situations, at 
home. Outpatient versus inpatient treatment should be a shared decision between the patient, their 
family and the health staff involved. The preference of the patient (e.g. in regards to treatment related 
costs for travel, hospitalization), existing comorbidities, the risk of developing side effects interfering 
with compliance and the capacity of the healthcare system for supervised administration as outpatient 
should all be considered.  
 
Discussion 
The updated evidence-based recommendations on therapeutic choices for g-HAT can be summarized 
as follows. Fexinidazole replaces pentamidine as first line treatment in patients with first stage g-
HAT, and replaces NECT as first line treatment in patients with second stage g-HAT with CSF WBC 
<100/µl. Patients of <6 years old or <20 kg bodyweight are excepted, as the safety and efficacy of 
fexinidazole in this age group is not established in the clinical trials and consequently, fexinidazole is 
not approved for this group. For patients with severe second stage g-HAT, defined by CSF WBC 
≥100/µl, NECT treatment is recommended. Without clinical suspicion of severe second stage, lumbar 
puncture can be avoided and fexinidazole given. Administration of fexinidazole should be done under 
the strict supervision of trained health staff.  
 
The above recommendations introduce important changes into clinical practice. Detailed guidelines 
for policy makers and medical staff managing patients, which follow from the four recommendations 
formulated by the guideline development group, can be found in the WHO Guidelines for the 
treatment of g-HAT.10 The algorithm shown in figure 1 summarizes these recommendations. Once a 
patient has been diagnosed with g-HAT, a detailed clinical assessment by a health professional who 
has adequate training and capacity to raise suspicion of severe second stage g-HAT has a decisive role 
(table 2). A correlation of neurological signs and symptoms with increasing CSF WBC count and 
especially with ≥100 WBC/µl has been shown.31 A patient not presenting with any of these suggestive 
symptoms and signs, is assumed at low probability of severe meningo-encephalitic stage and a lumbar 
puncture can be avoided, with the exception of patients of <6 years old or <20 kg bodyweight. 
Patients who do not need a lumbar puncture are treated with fexinidazole in case of high confidence in 
appropriate follow-up to detect relapse early. In the other patients, a CSF examination is required in 
order to establish the best treatment indication (figure 1). Based on the results of the CSF 
examination, the recommendations favour: 1) fexinidazole for patients (≥6 years and  ≥20 kg) with 
<100 WBC/µl CSF; 2) NECT for patients with ≥100 WBC/µl CSF, for children (<6 years or  <20 kg) 
with >5 WBC/µl and/or trypanosomes in CSF, or if the lumbar puncture is not done or if the CSF 
results are not interpretable; or 3) pentamidine for children (<6 years or <20 kg) with ≤5 WBC/µl and 
no trypanosomes in CSF. Fexinidazole treatment should be given in the outpatient setting only when 
there is confidence in concomitant food intake, full adherence, absence of psychiatric disorders, and a 
bodyweight ≥35 kg.7 As new relevant evidence emerges, the WHO guidance will be updated and 
completed.3,10,37 
 
These WHO guidelines for g-HAT treatment have a number of strengths. While previous HAT 
treatment guidelines relied more strongly on expert opinion and on non-systematic reviews of the 
evidence,3 this update followed the stricter methodology now mandatory in WHO.11 Decision-making 
was based on externally commissioned independent systematic reviews, and recommendations were 
formulated using the GRADE framework.15,17 The reviewers, methodologists and panel members all 
appreciated the use of the more rigorous approach as constructive. 
 
There are some limitations that remain.38 Studies for the evaluation of treatment modalities for HAT 
are particularly challenging.39,40 Due to the progressive decrease in cases of g-HAT, trials cannot enrol 
large patient groups and have limited statistical power.2 The trials have to be conducted in remote 
areas in sub-Saharan Africa with a long follow-up period of 24 months. For PICO 4, adherence to oral 
malaria treatment was used as a proxy of the expected adherence to fexinidazole. Accordingly, the 
certainty of evidence supporting the recommendations were rated as either very low certainty (PICO 
1, PICO 3 and PICO 4), or low certainty (PICO 2).   
 
Regarding the question on stratification (PICO 3), the panel had to judge how much the potential 
benefit of avoiding lumbar puncture outweighs the inferior efficacy of fexinidazole, particularly in 
severe second stage. On one hand, the EMA pointed out that the decision regarding the best treatment 
is complex and should still rely on a combination of clinical and CSF data as currently no other 
equivalent method exists.7 Fexinidazole data are so far limited to a modest number of patients treated 
(619 patients in the three main studies DNDiFEX004-006), and there are uncertainties around factors 
associated with relapse, hindering proposals for less-invasive stratification. On the other hand, 
avoiding a lumbar puncture and CSF microscopy has other positive implications for patients and the 
healthcare system.41 Lumbar puncture is relatively safe, even in low resource hospitals in rural Africa, 
but is painful, requires adequate material and know-how, and may induce headache, back pain, 
confusion and in rare cases cerebral herniation.42 Fear of lumbar puncture represents a barrier to HAT 
screening and for seeking treatment after HAT diagnosis.43,44 The step wise approach chosen exploits 
the advantages of fexinidazole. A primary clinical assessment followed by a lumbar puncture only in 
cases of suspected severe second stage, will identify patients with high CSF leucocytosis who should 
receive NECT to reduce the risk of treatment failure. Indeed, neurological and psychiatric symptoms 
increase significantly with CSF WBCs and indicate disease progression.31  
 
Even with the introduction of fexinidazole, systematic treatment of patients testing antibody positive 
in screening tests such as CATT/T.b. gambiense or in rapid diagnostic tests, but in whom no 
trypanosomes are detected in blood or lymph is not justified. Taking into account the limited positive 
predictive value of such serological tests at low prevalence, the national protocols set specific 
conditions for treating these patients, such as plasma titration, additional serological tests, clinical and 
epidemiological parameters. The national protocol may also require lumbar puncture or continued 
follow-up of seropositives with additional parasitological examinations. Once a patient is 
parasitologically confirmed or is considered as a g-HAT case based on additional criteria, the present 
treatment guidelines should be followed. 
 
Fexinidazole is a new drug that has been tested only in clinical trial settings. Being a 10-day oral 
treatment, frequently causing nausea and vomiting, and requiring concomitant food intake for full 
drug absorption, there is risk of non-compliance. Hence a need for systematic patient follow-up is 
high, even if this may be challenging with limited resources. In addition, relapses with fexinidazole 
may occur late, up to 12 to 24 months after treatment.7 Therefore, contrary to the situation with NECT 
and pentamidine, where, due to their high efficacy, systematic follow-up is currently not 
recommended,3 patients treated with fexinidazole should return for general examination at 6, 12, 18 
and 24 months after treatment, or at any time if symptoms reappear. In case of signs or symptoms 
suggesting a possibility of relapse, laboratory examinations of body fluids, including CSF, should be 
performed looking for trypanosomes and CSF leukocytosis. 
 
To date resistance to NECT has not been identified, however resistance to eflornithine and nifurtimox 
has been selected in the laboratory. Eflornithine resistance emerges when a transporter that carries the 
drug into the cell is lost.45 Nifurtimox resistance is associated with diminished activity of a 
nitroreductase enzyme required to activate the drug.46 The same enzyme is responsible for activation 
of fexinidazole and its diminished activity may cause cross-resistance between nifurtimox and 
fexinidazole.47 There is, therefore, a theoretical risk of resistance being selected to nifurtimox 
rendering parasites cross-resistant to fexinidazole, or the inverse. However, to date, the fitness of 
nitroreductase deficient parasites to be transmitted by tsetse flies has not been assessed. Given the 
mitochondrial localisation of that enzyme and prominent role of the mitochondrion in the tsetse fly 
stages of the parasites, it is not known whether parasites with diminished nitroreductase activity could 
be transmitted by tsetse flies. Furthermore, with relatively few doses of therapy currently given to 
HAT patients and low gambiense parasitaemias, the risk of resistance, and hence cross-resistance 
emerging, although theoretically possible, seems low. 
 
Taking into account the novelty of fexinidazole to treat g-HAT, some open questions and research 
priorities remain. The algorithm to decide which drug to use is relatively complicated due to the 
higher risk for relapse observed with fexinidazole if CSF WBC ≥100/µl and to the age and body 
weight limitations. Risk factors for relapse after fexinidazole treatment remain poorly characterized. 
In this context, the development and validation of clinical scores for treatment stratification is a 
research priority. An ongoing study on implementation, in particular on home-based treatment and 
adherence will yield further information on the potential of this drug in the future (ClinicalTrials.gov 
Identifier: NCT03025789). Taking into account that in vitro and in vivo studies have shown that 
fexinidazole kills Trypanosoma brucei rhodesiense48 and that the only treatment for second stage 
rhodesiense HAT is the highly toxic melarsoprol, a clinical trial testing efficacy of fexinidazole to 
treat this form of HAT has been initiated (NCT03974178). Further studies in children aged <6 years 
or <20 kg are needed to seek opportunities to improve treatment in this group. 
 
In conclusion, fexinidazole has the potential to simplify diagnosis and treatment of g-HAT and 
changes clinical practice in that direction. The next steps include the incorporation of the WHO 
guidelines into national treatment guidelines, appropriate training of health personnel, and field 
implementation, as well as putting in place a pharmacovigilance system. As fexinidazole will be 
deployed in areas poorly served by standard pharmacovigilance systems, a pro-active data collection 
is required, adapted to the local field constraints. Considering the currently limited evidence, and the 
ongoing additional studies on fexinidazole and on acoziborole, a new, single dose oral compound for 
treatment of all stages of g-HAT (NCT03087955), these WHO guidelines will be updated once new 
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Figure 1: Algorithm of WHO guidelines for the management of persons with gambiense HAT. 
a Presence of any symptom or sign consistent with severe second-stage g-HAT, detailed in table 2;  
b If the health facility has capacity for supervised administration as outpatient. DOT: directly observed therapy 
  
  
 
 
